Home The Word Brain	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	The Word Brain 2015 – Free PDF | Print | Web A short guide to fast language learning	Free Abstracts

Alzheimer's Disease

Free Subscription Articles published in Arch Neurol Retrieve available abstracts of 81 articles: HTML format Text format

Single Articles

December 2012
1. JAGUST W
   Apolipoprotein E, Neurodegeneration, and Alzheimer Disease.
   Arch Neurol. 2012 Dec 3:1-2. doi: 10.1001/jamaneurol.2013.
   PubMed     Text format    
   
   
   November 2012
2. DOROTHEE G , de Souza LC, Sarazin M, Aucouturier P, et al
   Plasma Anti-Amyloid-beta Autoantibodies in All Alzheimer Disease Types-Reply.
   Arch Neurol. 2012;69:1525-7.
   PubMed     Text format    
   
   
   
3. TREMOLIZZO L , Conti E, Appollonio I, Ferrarese C, et al
   Plasma Anti-Amyloid-beta Autoantibodies in All Alzheimer Disease Types.
   Arch Neurol. 2012;69:1525-7.
   PubMed     Text format    
   
   
   September 2012
4. WEINER MF
   Impact of Delirium on the Course of Alzheimer Disease.
   Arch Neurol. 2012 Sep 17:1-2. doi: 10.1001/archneurol.2012.2703.
   PubMed     Text format     Abstract available
   
   
   
5. HAJJAR I , Brown L, Mack WJ, Chui H, et al
   Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series.
   Arch Neurol. 2012 Sep 10:1-7. doi: 10.1001/archneurol.2012.1010.
   PubMed     Text format     Abstract available
   
   
   
6. BRICKMAN AM , Provenzano FA, Muraskin J, Manly JJ, et al
   Regional White Matter Hyperintensity Volume, Not Hippocampal Atrophy, Predicts Incident Alzheimer Disease in the Community.
   Arch Neurol. 2012 Sep 3:1-7. doi: 10.1001/archneurol.2012.1527.
   PubMed     Text format     Abstract available
   
   
   August 2012
7. CORIC V , van Dyck CH, Salloway S, Andreasen N, et al
   Safety and Tolerability of the gamma-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease.
   Arch Neurol. 2012 Aug 13:1-12. doi: 10.1001/archneurol.2012.2194.
   PubMed     Text format     Abstract available
   
   
   
8. JUN G , Vardarajan BN, Buros J, Yu CE, et al
   Comprehensive Search for Alzheimer Disease Susceptibility Loci in the APOE Region.
   Arch Neurol. 2012 Aug 6:1-10. doi: 10.1001/archneurol.2012.2052.
   PubMed     Text format     Abstract available
   
   
   
9. GUERREIRO RJ , Hardy J
   TOMM40 Association With Alzheimer Disease: Tales of APOE and Linkage Disequilibrium.
   Arch Neurol. 2012 Aug 6:1-2. doi: 10.1001/archneurol.2012.1935.
   PubMed     Text format    
   
   
   
10. HONIG LS
    Translational research in neurology: dementia.
    Arch Neurol. 2012;69:969-77.
    PubMed     Text format     Abstract available
    
    
    July 2012
11. WAGNER SL , Tanzi RE, Mobley WC, Galasko D, et al
    Potential Use of gamma-Secretase Modulators in the Treatment of Alzheimer Disease.
    Arch Neurol. 2012 Jul 16:1-4. doi: 10.1001/archneurol.2012.
    PubMed     Text format     Abstract available
    
    
    
12. DOECKE JD , Laws SM, Faux NG, Wilson W, et al
    Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease.
    Arch Neurol. 2012 Jul 16:1-8. doi: 10.1001/archneurol.2012.1282.
    PubMed     Text format     Abstract available
    
    
    
13. SOARES HD , Potter WZ, Pickering E, Kuhn M, et al
    Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease.
    Arch Neurol. 2012 Jul 16:1-8. doi: 10.1001/archneurol.2012.1070.
    PubMed     Text format     Abstract available
    
    
    
14. WANG HX
    Physical activity and AD-related pathology.
    Arch Neurol. 2012;69:940-1.
    PubMed     Text format    
    
    
    
15. KOYAMA A , Okereke OI, Yang T, Blacker D, et al
    Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.
    Arch Neurol. 2012;69:824-31.
    PubMed     Text format     Abstract available
    
    
    
16. LE PERA M , Urso E, Sprovieri T, Bossio S, et al
    Contribution of cerebrospinal fluid thymosin beta4 levels to the clinical differentiation of Creutzfeldt-Jakob disease.
    Arch Neurol. 2012;69:868-72.
    PubMed     Text format     Abstract available
    
    
    
17. JUNG S , Zarow C, Mack WJ, Zheng L, et al
    Preservation of neurons of the nucleus basalis in subcortical ischemic vascular disease.
    Arch Neurol. 2012;69:879-86.
    PubMed     Text format     Abstract available
    
    
    June 2012
18. DOROTHEE G , Bottlaender M, Moukari E, de Souza LC, et al
    Distinct Patterns of Antiamyloid-beta Antibodies in Typical and Atypical Alzheimer DiseaseDistinct Patterns of Anti-Abeta Antibodies and AD.
    Arch Neurol. 2012 Jun 18:1-5. doi: 10.1001/archneurol.2012.
    PubMed     Text format     Abstract available
    
    
    
19. RINGMAN JM , Elashoff D, Geschwind DH, Welsh BT, et al
    Plasma Signaling Proteins in Persons at Genetic Risk for Alzheimer Disease: Influence of APOE GenotypePlasma Biomarkers and AD Genetic Risk.
    Arch Neurol. 2012;69:757-64.
    PubMed     Text format     Abstract available
    
    
    
20. DESIKAN RS , McEvoy LK, Thompson WK, Holland D, et al
    Amyloid-beta--associated clinical decline occurs only in the presence of elevated P-tau.
    Arch Neurol. 2012;69:709-13.
    PubMed     Text format     Abstract available
    
    
    
21. HOLTZMAN DM
    CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important.
    Arch Neurol. 2012;69:691-2.
    PubMed     Text format    
    
    
    May 2012
22. SMITH GS , Laxton AW, Tang-Wai DF, McAndrews MP, et al
    Increased Cerebral Metabolism After 1 Year of Deep Brain Stimulation in Alzheimer Disease.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
23. 
    Insulin and Alzheimer disease-reply.
    Arch Neurol. 2012;69:670-1.
    PubMed     Text format    
    
    
    
24. 
    Insulin and Alzheimer disease.
    Arch Neurol. 2012;69:670-1.
    PubMed     Text format    
    
    
    
25. WHITWELL JL , Wiste HJ, Weigand SD, Rocca WA, et al
    Comparison of imaging biomarkers in the Alzheimer disease neuroimaging initiative and the mayo clinic study of aging.
    Arch Neurol. 2012;69:614-22.
    PubMed     Text format     Abstract available
    
    
    
26. LANDAU SM , Marks SM, Mormino EC, Rabinovici GD, et al
    Association of lifetime cognitive engagement and low beta-amyloid deposition.
    Arch Neurol. 2012;69:623-29.
    PubMed     Text format     Abstract available
    
    
    April 2012
27. IRWIN DJ , McMillan CT, Toledo JB, Arnold SE, et al
    Comparison of Cerebrospinal Fluid Levels of Tau and Abeta 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
28. BLENNOW K , Zetterberg H, Rinne JO, Salloway S, et al
    Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
29. BOXER AL , Garbutt S, Seeley WW, Jafari A, et al
    Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease.
    Arch Neurol. 2012;69:509-17.
    PubMed     Text format     Abstract available
    
    
    March 2012
30. GALASKO DR , Peskind E, Clark CM, Quinn JF, et al
    Antioxidants for Alzheimer Disease: A Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
31. BERNICK C , Cummings J, Raman R, Sun X, et al
    Age and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
32. JACK CR JR , Vemuri P, Wiste HJ, Weigand SD, et al
    Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
33. REITZ C , Conrad C, Roszkowski K, Rogers RS, et al
    Effect of Genetic Variation in LRRTM3 on Risk of Alzheimer Disease.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
34. GLODZIK L , Galvin J, Pirraglia E, de Leon M, et al
    Ordering of Alzheimer disease biomarkers.
    Arch Neurol. 2012;69:414.
    PubMed     Text format    
    
    
    
35. CAGLAYAN S , Bauerfeind A, Schmidt V, Carlo AS, et al
    Identification of Alzheimer Disease Risk Genotype That Predicts Efficiency of SORL1 Expression in the Brain.
    Arch Neurol. 2012;69:373-9.
    PubMed     Text format     Abstract available
    
    
    
36. IRIZARRY MC , Jin S, He F, Emond JA, et al
    Incidence of new-onset seizures in mild to moderate Alzheimer disease.
    Arch Neurol. 2012;69:368-72.
    PubMed     Text format     Abstract available
    
    
    February 2012
37. MORRIS JC
    Revised Criteria for Mild Cognitive Impairment May Compromise the Diagnosis of Alzheimer Disease Dementia.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
38. MOGHEKAR A , Goh J, Li M, Albert M, et al
    Cerebrospinal fluid Abeta and tau level fluctuation in an older clinical cohort.
    Arch Neurol. 2012;69:246-50.
    PubMed     Text format     Abstract available
    
    
    January 2012
39. VAN HIMBERGEN TM , Beiser AS, Ai M, Seshadri S, et al
    Biomarkers for Insulin Resistance and Inflammation and the Risk for All-Cause Dementia and Alzheimer Disease: Results From the Framingham Heart Study.
    Arch Neurol. 2012.
    PubMed     Text format     Abstract available
    
    
    
40. RINGMAN JM , Schulman H, Becker C, Jones T, et al
    Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.
    Arch Neurol. 2012;69:96-104.
    PubMed     Text format     Abstract available
    
    
    
41. ANCES BM , Benzinger TL, Christensen JJ, Thomas J, et al
    11C-PiB Imaging of Human Immunodeficiency Virus-Associated Neurocognitive Disorder.
    Arch Neurol. 2012;69:72-7.
    PubMed     Text format     Abstract available
    
    
    December 2011
42. LOGUE MW , Schu M, Vardarajan BN, Buros J, et al
    A Comprehensive Genetic Association Study of Alzheimer Disease in African Americans.
    Arch Neurol. 2011;68:1569-1579.
    PubMed     Text format     Abstract available
    
    
    November 2011
43. SABBAGH MN , Fleisher A, Chen K, Rogers J, et al
    Positron Emission Tomography and Neuropathologic Estimates of Fibrillar Amyloid-beta in a Patient With Down Syndrome and Alzheimer Disease.
    Arch Neurol. 2011;68:1461-6.
    PubMed     Text format     Abstract available
    
    
    
44. HARDY J , Guerreiro R, Lovestone S
    Clusterin as an Alzheimer biomarker.
    Arch Neurol. 2011;68:1459-60.
    PubMed     Text format    
    
    
    
45. SHEPARDSON NE , Shankar GM, Selkoe DJ
    Cholesterol Level and Statin Use in Alzheimer Disease: II. Review of Human Trials and Recommendations.
    Arch Neurol. 2011;68:1385-92.
    PubMed     Text format     Abstract available
    
    
    
46. JAGUST WJ
    Amyloid imaging: liberal or conservative? Let the data decide.
    Arch Neurol. 2011;68:1377-8.
    PubMed     Text format    
    
    
    October 2011
47. OSTROWITZKI S , Deptula D, Thurfjell L, Barkhof F, et al
    Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
48. XIONG C , Roe CM, Buckles V, Fagan A, et al
    Role of family history for Alzheimer biomarker abnormalities in the adult children study.
    Arch Neurol. 2011;68:1313-9.
    PubMed     Text format     Abstract available
    
    
    
49. SHEPARDSON NE , Shankar GM, Selkoe DJ
    Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies.
    Arch Neurol. 2011;68:1239-44.
    PubMed     Text format     Abstract available
    
    
    
50. LO RY , Hubbard AE, Shaw LM, Trojanowski JQ, et al
    Longitudinal change of biomarkers in cognitive decline.
    Arch Neurol. 2011;68:1257-66.
    PubMed     Text format     Abstract available
    
    
    September 2011
51. WINGO TS , Lah JJ, Levey AI, Cutler DJ, et al
    Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
52. CRAFT S , Baker LD, Montine TJ, Minoshima S, et al
    Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
53. MULLER U , Winter P, Graeber MB
    Alois Alzheimer's Case, Auguste D., Did Not Carry the N141I Mutation in PSEN2 Characteristic of Alzheimer Disease in Volga Germans.
    Arch Neurol. 2011;68:1210-1.
    PubMed     Text format    
    
    
    
54. SCHMIDT C , Wolff M, Weitz M, Bartlau T, et al
    Rapidly progressive Alzheimer disease.
    Arch Neurol. 2011;68:1124-30.
    PubMed     Text format     Abstract available
    
    
    
55. ROE CM , Fagan AM, Grant EA, Marcus DS, et al
    Cerebrospinal fluid biomarkers, education, brain volume, and future cognition.
    Arch Neurol. 2011;68:1145-51.
    PubMed     Text format     Abstract available
    
    
    August 2011
56. JACK CR JR , Vemuri P, Wiste HJ, Weigand SD, et al
    Evidence for Ordering of Alzheimer Disease Biomarkers.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
57. SABUNCU MR , Desikan RS, Sepulcre J, Yeo BT, et al
    The Dynamics of Cortical and Hippocampal Atrophy in Alzheimer Disease.
    Arch Neurol. 2011;68:1040-1048.
    PubMed     Text format     Abstract available
    
    
    
58. CRUCHAGA C , Nowotny P, Kauwe JS, Ridge PG, et al
    Association and Expression Analyses With Single-Nucleotide Polymorphisms in TOMM40 in Alzheimer Disease.
    Arch Neurol. 2011;68:1013-1019.
    PubMed     Text format     Abstract available
    
    
    
59. SONNEN JA , Santa Cruz K, Hemmy LS, Woltjer R, et al
    Ecology of the aging human brain.
    Arch Neurol. 2011;68:1049-56.
    PubMed     Text format     Abstract available
    
    
    July 2011
60. FLEISHER AS , Chen K, Liu X, Roontiva A, et al
    Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
61. VILLEMAGNE VL , Okamura N, Pejoska S, Drago J, et al
    In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
    Arch Neurol. 2011;68:905-12.
    PubMed     Text format     Abstract available
    
    
    
62. LANDT J , D'Abrera JC, Holland AJ, Aigbirhio FI, et al
    Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar beta-amyloid in adults with down syndrome: safety, acceptability, and feasibility.
    Arch Neurol. 2011;68:890-6.
    PubMed     Text format     Abstract available
    
    
    June 2011
63. ROSENBERG RN
    Treat Alzheimer Disease Before It Is Symptomatic.
    Arch Neurol. 2011.
    PubMed     Text format    
    
    
    
64. HACHINSKI V
    Stroke and Alzheimer disease: fellow travelers or partners in crime?
    Arch Neurol. 2011;68:797-8.
    PubMed     Text format    
    
    
    
65. NELSON LD , Siddarth P, Kepe V, Scheibel KE, et al
    Positron emission tomography of brain beta-amyloid and tau levels in adults with Down syndrome.
    Arch Neurol. 2011;68:768-74.
    PubMed     Text format     Abstract available
    
    
    
66. BAYER-CARTER JL , Green PS, Montine TJ, VanFossen B, et al
    Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment.
    Arch Neurol. 2011;68:743-52.
    PubMed     Text format     Abstract available
    
    
    May 2011
67. FAGAN AM , Shaw LM, Xiong C, Vanderstichele H, et al
    Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
68. DAVIGLUS ML , Plassman BL, Pirzada A, Bell CC, et al
    Risk Factors and Preventive Interventions for Alzheimer Disease: State of the Science.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
69. LASKE C
    Blood-based biomarkers in Alzheimer disease.
    Arch Neurol. 2011;68:685-6.
    PubMed     Text format    
    
    
    
70. ATRI A , O'Brien JL, Sreenivasan A, Rastegar S, et al
    Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer disease clinical trials.
    Arch Neurol. 2011;68:599-606.
    PubMed     Text format     Abstract available
    
    
    
71. YAFFE K , Middleton LE, Lui LY, Spira AP, et al
    Mild cognitive impairment, dementia, and their subtypes in oldest old women.
    Arch Neurol. 2011;68:631-6.
    PubMed     Text format     Abstract available
    
    
    
72. CRUCHAGA C , Graff C, Chiang HH, Wang J, et al
    Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels.
    Arch Neurol. 2011;68:581-6.
    PubMed     Text format     Abstract available
    
    
    April 2011
73. HYMAN BT
    Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease.
    Arch Neurol. 2011.
    PubMed     Text format    
    
    
    
74. SCHNEIDER LS , Dagerman KS, Higgins JP, McShane R, et al
    Lack of Evidence for the Efficacy of Memantine in Mild Alzheimer Disease.
    Arch Neurol. 2011.
    PubMed     Text format     Abstract available
    
    
    
75. SAKURAI T
    Targets of the Peroxisome Proliferator-Activated Receptor {gamma} Agonist Trials for the Prevention of Alzheimer Disease.
    Arch Neurol. 2011;68:542.
    PubMed     Text format    
    
    
    March 2011
76. KUHLMANN D
    Primum non nocere.
    Arch Neurol. 2011;68:397-8.
    PubMed     Text format    
    
    
    
77. SETO-SALVIA N , Clarimon J, Pagonabarraga J, Pascual-Sedano B, et al
    Dementia Risk in Parkinson Disease: Disentangling the Role of MAPT Haplotypes.
    Arch Neurol. 2011;68:359-64.
    PubMed     Text format     Abstract available
    
    
    
78. WOMACK KB , Diaz-Arrastia R, Aizenstein HJ, Arnold SE, et al
    Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors.
    Arch Neurol. 2011;68:329-37.
    PubMed     Text format     Abstract available
    
    
    February 2011
79. REIJMER Y , Biessels GJ
    Vascular risk scores for dementia: age matters.
    Arch Neurol. 2011;68:267.
    PubMed     Text format    
    
    
    
80. GEERLINGS MI , Vergouwe Y
    Improving risk scores for dementia.
    Arch Neurol. 2011;68:267-8.
    PubMed     Text format    
    
    
    
81. SOJKOVA J , Driscoll I, Iacono D, Zhou Y, et al
    In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults.
    Arch Neurol. 2011;68:232-40.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: